HM-2002 / Shanghai CirCode Biomed - LARVOL DELTA

CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world's first circular RNA drug being administrated in patients (ACROFAN) - "Shanghai CirCode Biomed Co. Ltd...recently announced that its leading pipeline HM2002 received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for ischemic heart disease on May 30, 2025."

IND • Cardiovascular • Coronary Artery Disease

First-in-Human Pilot Study of Epicardial Circular RNA-HM2002 Injection in CABG for Ischemic Heart Failure (clinicaltrials.gov) - P1 | N=3 | Active, not recruiting | Sponsor: Ruijin Hospital | Recruiting ➔ Active, not recruiting

Circular RNA • Enrollment closed • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure